Article Sidebar
Main Article Content
Abstract
Background. Worldwide incidence of breast cancer is still high. Surgical intervention is mainly used as primary treatment with other supplementary modality such as chemoterapy, radioterapy, and immunotherapy such as Artemisia vulgaris (AV). This study was aimed to analyze the increase in apoptotic effect response of adriamycin-cyclophosphamide on C3H mice model of adenocarcinoma breast cancer provided with Artemisia vulgaris extract.
Methods. This research is a post-test only control group design. Twenty four C3H mice were randomly selected and put into 4 groups: K (control group), P1 (Chemoterapy only), P2 (extract only) and P3 (chemoterapy-extract combination). Breast adenocarcinoma was taken from inoculated donor mice. Chemoterapy regiment of 0.18 mg Adriamycin and 1.8 mg Cyclophosphamide were given in 2 cycles. Thirteen miligrams (0.2 mL) of AV extract was given orally once daily. Apoptotic index and Caspase-8 expression were graded with immunohistochemistry stain.
Results. Mean value of p53 and caspase-8 expression in K, P1, P2, P3 groups were 22,06 + 1,73, 37,16 + 1,20, 24,60 + 1,08, 39,78 + 1,19 and 17.16 + 1,28, 26,20 + 1,11, 24.60 + 1,08, 39,78 + 1,19, respectively. Statistical analysis showed significant differences in apoptotic index between group K vs P1, P3 (p = 0,001), P1 vs P2 (p = 0,001), P1 vs P3 (p = 0,035), P2 vs P3 (p = 0,001) and for Caspase-8 between K vs P1, P3 (p = 0,001), K vs P2 (p = 0,048), P1 vs P2 (p = 0,001), P1 vs P3 (p = 0,039), P2 vs P3 (p = 0,001). We found a significant correlation between apoptotic index and Caspase-8 expression. (p = 0,047 and r = 0,883).
Conclusion. Artemisia vulgaris can increase the adriamycin-cyclophosphamide chemoterapy effectiveness on C3H Mice Model of Breast Adenocarcinoma.
Keywords
Article Details
As our aim is to disseminate original research article, hence the publishing right is a necessary one. The publishing right is needed in order to reach the agreement between the author and publisher. As the journal is fully open access, the authors will sign an exclusive license agreement.
The authors have the right to:
- Share their article in the same ways permitted to third parties under the relevant user license.
- Retain copyright, patent, trademark and other intellectual property rights including research data.
- Proper attribution and credit for the published work.
For the open access article, the publisher is granted to the following right.
- The non-exclusive right to publish the article and grant right to others.
- For the published article, the publisher applied for the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
